Table 1.
Baseline features and response to frontline treatment of the 727 patients of the series.
| Characteristics | Entire cohort (n = 727) | Decade 1 (1980–1989) (n = 79) | Decade 2 (1990–1999) (n = 163) | Decade 3 (2000–2009) (n = 254) | Decade 4 (2010–2017) (n = 231) | P value |
|---|---|---|---|---|---|---|
| Age, median (range) | 57 (23–93) | 54 (24–85) | 54 (24–88) | 57 (23–93) | 61 (26–91) | <0.001 |
| Female sex (%) | 389 (53) | 33 (42) | 92 (56) | 138 (54) | 126 (54) | NS |
| Histologic grade 1 or 2 (%) | 419 (84) | NA | 59 (89) | 184 (83) | 172 (83) | NS |
| ECOG ≥ 2 (%) | 64 (9) | 16 (21) | 18 (11) | 15 (6) | 15 (7) | <0.001 |
| Ann Arbor stage IV (%) | 433 (60) | 45 (57) | 97 (62) | 149 (59) | 142 (62) | NS |
| Elevated LDH (%) | 126 (19) | 17 (25) | 30 (22) | 42 (19) | 37 (17) | NS |
| Elevated β2- microglobulin (%) | 241 (43) | 4 (57) | 45 (36) | 80 (37) | 112 (52) | 0.005 |
| High-risk FLIPI (%) | 163 (25) | 20 (30) | 38 (27) | 39 (17) | 66 (29) | 0.009 |
| CR/CRu (%) | 437 (64) | 37 (48) | 85 (53) | 177 (73) | 138 (70) | <0.001 |
| PR (%) | 186 (28) | 33 (42) | 57 (36) | 45 (19) | 51 (26) | |
| Refractory disease (%) | 54 (8) | 8 (10) | 18 (11) | 19 (8) | 9 (4) |
Response data are calculated only on the 677 patients of the series who received any treatment. Data concerning β2-microglobulin levels should be interpreted with caution for decade 1, since only seven patients had available data.
ECOG Eastern Cooperative Oncology Group, LDH lactate dehydrogenase, FLIPI Follicular Lymphoma International Prognostic Index, NA not available, NS not statistically significant, CRu complete response unconfirmed, PR partial response.